Latest Biologicals News

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Farm Pride Foods Ltd reported a 16% revenue increase to $118.3 million and a 53% jump in net profit to $10.2 million for FY26, underpinned by operational improvements and strategic capital investments.

Delegat Group (NZX:DGL) reported a 20% jump in operating NPAT to NZD 61.5 million for FY26, driven by record EBITDA and a 4% rise in global case sales. The Board declared a 22-cent dividend, up 10%, while net debt fell by NZD 51.8 million.

St George Mining has formally begun environmental permitting for its Araxá Project in Brazil, submitting key assessments to Minas Gerais regulators as it moves toward developing a rare earths and niobium mine.

Zeotech Limited’s zeoteCH4® technology slashed methane emissions by an average 92% in a six-month landfill trial at North Burnett Regional Council, confirming its promise as a practical methane mitigation solution under real-world conditions.

IDT Australia reports a sharp turnaround in FY26 with a 66% reduction in net loss and an 85% improvement in EBITDA, underpinned by a strategic reset and targeted investments in manufacturing capabilities.

Whitehaven Coal reported a 29% drop in underlying net profit to $227 million for FY26, despite record safety outcomes and successful debt refinancing that lowered funding costs and extended maturities.

EBOS Group posted a solid FY26, growing revenue nearly 10% to $13.5 billion and underlying EBITDA 5% to $614 million, while completing a major distribution centre renewal program. The company maintains its final dividend and sets a confident growth outlook for FY27.

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

RLF AgTech posted a seasonally strong June quarter with $7.1 million in cash receipts, driven by record pre-season payments in China and tight cost control that brought operating cash flow close to breakeven.